Skip to main navigation
  • About Us
    • Our Living Values
    • Senior Management
    • Board of Directors
    • Collaborations
    • Corporate Compliance & Ethics
    • Contact Us
  • Products
    • MARGENZA®
  • Pipeline
    • MGC018 (B7-H3)
    • Enoblituzumab (anti-B7-H3)
    • Lorigerlimab (PD-1 × CTLA-4)
    • Tebotelimab (PD-1 × LAG-3)
    • IMGC936 (ADAM9)
    • MGD024 (CD123 × CD3)
    • Retifanlimab (PD-1)
    • MGD014 (HIV × CD3)
  • Platforms
    • DART® and TRIDENT®
    • Fc Optimization
  • Patients
    • Clinical Trials
    • Expanded Access
  • Investors

    Investor Relations

    • Press Releases
    • Events & Presentations
    • Corporate Governance
      • Senior Management
      • Board of Directors
      • Committee Composition
      • Contact the Board
    • Financials & Filings
      • SEC Filings
      • Quarterly Results
      • Key Metrics
    • Stock Information
      • Historic Stock Lookup
      • Investment Calculator
      • Analyst Coverage
      • Ownership Profile
    • Investor FAQs
    • Publications
    • Contact Investor Relations
  • Careers at Macrogenics
    • Current Openings
    • Employee Benefits

Financials & Filings

Shareholder Tools


  • Facebook
  • LinkedIn
  • Twitter
  • RSS

Breadcrumb

Home Investors Financials & Filings

Financials & Filings

Show all

2021

Q4
  • MacroGenics Provides Update on Corporate Progress and 2021 Financial Results
  • Form 10-K

PROXY STATEMENTS

Filing date View
Apr 8, 2022 View HTML
0001125345-22-000039.pdf
0001125345-22-000039.xls
Apr 8, 2022 View HTML
0001125345-22-000040.pdf
0001125345-22-000040.xls

FORM 10-K

Filing date View
Feb 24, 2022 View HTML
0001125345-22-000013.pdf
0001125345-22-000013.xls
EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA
Feb 25, 2021 View HTML
0001125345-21-000035.pdf
0001125345-21-000035.xls
EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA

FORM 10-Q

Filing date View
Nov 3, 2022 View HTML
0001125345-22-000104.pdf
0001125345-22-000104.xls
EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA
Aug 8, 2022 View HTML
0001125345-22-000090.pdf
0001125345-22-000090.xls
EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA
    • About Us
    • Our Living Values
    • Senior Management
    • Board of Directors
    • Collaborations
    • Products
    • MARGENZA™
    • Pipeline
    • MGC018 (B7-H3)
    • Enoblituzumab (anti-B7-H3)
    • Lorigerlimab (PD-1 × CTLA-4)
    • Tebotelimab (PD-1 × LAG-3)
    • IMGC936 (ADAM9)
    • Retifanlimab (PD-1)
    • MGD014 (HIV × CD3)
    • Platforms
    • DART® and TRIDENT®
    • Fc Optimization
    • Patients
    • Clinical Trials
    • Expanded Access
    • Investors
    • Footer investor menu

      • Press Releases
      • Events & Presentations
      • Corporate Governance
      • Financials & Filings
      • Stock Information
      • Investor FAQs
      • Publications
      • Contact Us
    • Careers
    • Current Openings
    • Employee Benefits
©2023 MacroGenics, Inc.
  • Contact Us
  • Site Map
  • Privacy Policy
  • Terms of Use
  • Other Notices